“We are broadening our technical expertise with a management team that is well-recognized in the field of pharmaceutical development and analytical services. This dovetails with Columbia’s historical expertise with drug development, and should enable us to enhance our level of technical service to our commercial partners. By transitioning CRINONE quality management and technical support to Molecular Profiles, within close proximity of our CRINONE manufacturing sites and supply chain management in Europe, we anticipate significant improvements in efficiencies and greater responsiveness to Merck Serono, our largest customer for CRINONE,” concluded Mr. Condella.On an unaudited basis, Molecular Profiles’ recorded approximately $9 million in revenues for its fiscal year ended July 31, 2013. The company maintained a CAGR of 15% and 14% for revenue and EBITDA, respectively, over the trailing four fiscal years 2. Frank Condella and Nikin Patel will host a conference call with webcast slide presentation to discuss the Molecular Profiles acquisition as follows:
|Date:||Thursday, September 12, 2013|
|Time:||8:30 am EDT / 1:30 pm BST|
|Dial-in numbers:||(877) 303-9483 (U.S. & Canada) or (760) 666-3584 (international)|
|Live webcast and slide||www.columbialabs.com, under 'Investor,' or click here|
CRINONE ® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.Molecular Profiles™ is a registered trademark of Molecular Profiles Ltd. 1 EBITDA, defined as earnings before interest, tax, depreciation and amortisation, is a non-GAAP indicator of a company's financial performance. 2 Based on Molecular Profiles’ financial statements reported under U.K. GAAP, as audited by Grant Thornton U.K. LLP, for fiscal years ended July 31, 2010-2012, and unaudited financial statements for its fiscal year ended July 31, 2013.